HeartMate 3 LVAD Therapy

A treatment for those with advanced heart failure

HeartMate 3 LVAD Therapy

HeartMate 3 LVAD Therapy from Abbott

Abbott has been a leader in heart pump technology for more than 20 years. You should feel confident with a HeartMate 3™ LVAD to treat your heart failure. Here's why:

Abbott’s heart pumps have set the standard in LVAD therapy. The HeartMate 3 LVAD is the most advanced LVAD yet. It is the only LVAD that uses a patented technology which helps protect the blood as it flows through the pump.

In the largest LVAD clinical trial* ever conducted, HeartMate 3 LVAD had outstanding clinical results and a high survival rate similar to heart transplant 2 years after surgery.1,2+


Living with HeartMate 3 LVAD for Heart Failure

Listen to people tell their HeartMate 3 LVAD stories and how they are living their lives to the fullest.

HeartMate 3 LVAD Therapy Helps People with Advanced Heart Failure:1

  • Reverse the symptoms of heart failure
  • Live longer
  • Live active, full lives with a better quality of life

HeartMate 3 LVAD Therapy Can Help Kids with Heart Failure Too

Heart failure has devastating consequences in the United States and while the average age of patients is much higher, it can affect the lives of children and their families. For many types of pediatric heart failure patients, receiving a heart transplant is the gold standard in care. While waiting for a heart transplant, some children may require a left ventricular assist device (LVAD) to support their heart until a donor heart is available. In addition, children who are not current candidates for heart transplantation may receive an LVAD to allow the child to resume a sense of normal life.

Some children need an LVAD device

Advanced Cardiac Therapies Improving Outcomes Network (ACTION)

Abbott collaborated with the Advanced Cardiac Therapies Improving Outcomes Network (ACTION) to advocate the importance of the HeartMate 3 LVAD as a life-saving resource for some of their most vulnerable patients.

Learn more about the ACTION Learning Network and explore additional resources.

Advanced Cardiac Therapies

Understanding HeartMate 3 LVAD Therapy

Watch this video to learn about HeartMate 3 LVAD therapy and how it can help people with advanced heart failure.

Associated risks of LVAD therapy can include bleeding, stroke, thrombosis and other possible adverse events.


“When my cardiologist told me I qualified for the HeartMate 3, I asked if they could put it in that afternoon. Ever since I've had my HeartMate 3, every day has been just amazing.”

— Dave V., HeartMate 3 LVAD Recipient.

This testimonial relates an account of an individual’s response to the treatment. This patient’s account is genuine, typical and documented. However, it does not provide any indication, guide, warranty or guarantee as to the response other persons may have to the treatment. Responses to the treatment discussed can and do vary and are specific to the individual patient.

Live a More Active Life With an LVAD

See what real people have to say about life after receiving their HeartMate 3 LVAD.

Live a more active life

Additional Information

These materials are not intended to replace your doctor’s advice or information. For any questions or concerns you may have regarding the medical procedures, devices and/or your personal health, please discuss these with your physician.

* A clinical trial is a type of research that studies a test or treatment given to people.
+ 82% 2-year survival for adult heart transplant patients between 2009 and 2015.

Results based on published data from multicenter experience and separate studies, which may involve different patient populations and other variables. Not a head-to-head comparison. Data presented for informational purposes only.


  1. Mehra MR, Uriel N, Naka Y, et al. A Fully Magnetically Levitated Ventricular Assist Device-Final Report. N Engl J Med. 2019;380:1618-1627.
  2. Khush KK, Cherikh WS, Chambers DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-fifth Adult Heart Transplant Report-2018; Focus Theme: Multiorgan Transplantation. J Heart Lung Transplant. 2018;37:1155-1168.

MAT-2108557 v5.0